進行卵巣がんにおけるネオアジュバント化学療法にベバシズマブを追加する利点と落とし穴:メタ分析
Zeyi Zhao1, Lei Cheng2, Xin Tong3
1Department of Oncology, Jining NO.1 People's Hospital, Jining, China.
Future oncology (London, England)
|August 22, 2025
まとめ
進んだ卵巣がんの新補助化学療法にベバシズマブを添加すると,最適な細胞縮小率が改善するが,胃腸の穿孔のリスクは増加する. 卵巣がん患者の有効性と毒性のバランスを取るためにさらなる研究が必要です.
科学分野:
- 腫瘍学
- 婦人科腫瘍学
- 臨床薬理学
背景:
- 進行段階の卵巣がん (AOC) は,治療に重大な課題を伴う.
- 新補助化学療法 (NACT) はAOCの標準的なアプローチです.
- 抗血管新生剤であるベバシズマブは,NACTの有効性を高めるために研究されている.
研究 の 目的:
- AOCでベバシズマブとNACTの組み合わせの有効性と毒性を評価する.
- ベバシズマブ-NACTと標準NACTのアウトカムを比較する
主な方法:
- ランダム化臨床試験,コホート研究,症例シリーズの体系的なレビューとメタ分析.
- PubMed,EMBASE,Scopus,Web of Scienceのデータベースを 検索しました
- 2010年11月から2024年12月までの間に発表された研究も含まれています.
主要な成果:
- ベバシズマブNACTは,最適な細胞減少率 (RR:1.17,P=0. 02) を有意に増加させた.
- 完全な細胞縮小,手術の実施,創傷合併症,血栓形成,または感染症において有意な差異は観察されなかった.
- ベバシズマブNACT群では胃腸の穴の危険性が高かった (RR: 6. 97, P=0. 02).
結論:
- ベバシズマブをNACTに添加すると,AOCにおける最適な細胞縮小の可行性を高めます.
- 併用療法では胃腸の穴が開くリスクが高くなります.
- ベバシズマブNACTを使用する際には,慎重に患者の選択とモニタリングを行うことが重要です.
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
440
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
440
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


